Q-omics provides the consensus-scored PADI1 profile across patient tissues and cancer cell-line models. PADI1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PADI1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PADI1 RNA expression shows 13,305 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where PADI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PADI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PADI1 survival associations across molecular data types. PADI1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PADI1 RNA expression–survival associations across cancer types. High PADI1 expression shows unfavorable associations in UVM, LGG, PAAD, KIRC and SKCM, but favorable associations in UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PADI1 RNA expression.
This table summarizes PADI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PADI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PADI1 shows lower tumor expression in HNSC and higher tumor expression in KIRC, BLCA, LUAD, THCA and BRCA. The KIRC box plot shows higher PADI1 RNA expression in tumor versus normal tissue (log2 FC = +1.237, t-test p < 0.001).
This table shows molecular features associated with PADI1 in patient tissues and cancer cell lines. In patient samples, PADI1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PADI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and PANCREAS.
